Pharmacoeconomic evaluation of roxithromycin versus amoxycillin/clavulanic acid in a community-acquired lower respiratory tract infection study
- 1 January 1995
- journal article
- clinical trial
- Published by Springer Nature in Infection
- Vol. 23 (1) , S21-S24
- https://doi.org/10.1007/bf02464955
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Roxithromycin 150 mg b.i.d. versus amoxycillin 500 mg/clavulanic acid 125 mg t.i.d. for the treatment of lower respiratory tract infections in general practiceInfection, 1995
- Roxithromycin versus Cefaclor in Lower Respiratory Tract InfectionPharmacoEconomics, 1993
- Amoxicillin/Clavulanic AcidDrugs, 1990
- RoxithromycinDrugs, 1989